Sleep Apnea and Sexual Health
Half of men with sleep apnea in one trial had erectile dysfunction. The surprise is in the treatment data: the clearest benefit from CPAP was measured in women, not men.
This gets discussed almost entirely as a men's erectile dysfunction question, and the evidence does not support that framing. The treatment data points somewhere unexpected.
The association
A randomised trial in patients with obstructive sleep apnea found an erectile dysfunction prevalence of 51% (PLoS One, 2018).
Patients with erectile dysfunction were older, had greater waist-to-hip ratios, were more frequently on pharmacological treatment, and had higher glucose levels than those without [PLoS One 2018].
That list is the interpretive problem in miniature. Age, central adiposity, medication burden and glucose are each independently associated with erectile dysfunction and with sleep apnea. So while the association between apnea and erectile dysfunction is real and reproducible, how much is the apnea itself rather than the company it keeps is not settled by prevalence figures.
Plausible mechanisms exist: intermittent hypoxia impairing endothelial function — the same vascular mechanism behind apnea's cardiovascular associations — sleep fragmentation, and effects on the gonadal axis. Snoring and testosterone.
What treatment does, for men
Here the trial is more instructive than the prevalence.
After CPAP, there were significant improvements in erectile function (mean change +4.6, SD 7.9; p = 0.002), overall satisfaction (+1, SD 2.2; p = 0.035) and sexual satisfaction (+2.1, SD 4.3; p = 0.003) [PLoS One 2018].
Read that and CPAP looks effective. Then read the next sentence.
Between the study arms, only sexual satisfaction differed significantly (p = 0.027). Erectile function did not (p = 0.060) [PLoS One 2018].
That gap between within-group improvement and between-arm difference is the whole lesson. Both arms improved; the controlled comparison mostly did not separate them. Which is what you would expect if a meaningful part of the improvement were expectation, attention, or regression to the mean rather than the treatment.
CPAP also did not affect psychological, hormonal or biochemical profiles [PLoS One 2018].
The authors' conclusion is appropriately cautious: the study confirmed the relationship between apnea and erectile dysfunction and suggests screening for erectile dysfunction in apnea patients, but could not conclusively determine whether CPAP is an effective stand-alone treatment for it, despite the positive sexual-satisfaction result [PLoS One 2018].
What treatment does, for women — the unexpected part
A cohort study followed 182 participants with severe apnea — 115 (63.2%) men, mean age 47.2 years, mean AHI 32.5 events per hour — and compared sexual quality of life at 12 months between CPAP users and non-users (JAMA Otolaryngology–Head & Neck Surgery, 2018).
Overall, 72 CPAP users averaging 6.4 hours a night improved more than 110 non-users: 0.7 against 0.1 on the sexual quality-of-life score, a difference of 0.54 (95% CI, 0.18–0.90), effect size 0.47 [JAMA Oto 2018]. After adjustment for age, sex, race and ethnicity, marital status, income, education, BMI, AHI and a comorbidity index, the adjusted difference was 0.49 (95% CI, 0.09–0.89), effect size 0.43 [ibid].
Then the subgroup analysis:
| Group | Adjusted difference (95% CI) | Effect size |
|---|---|---|
| Women | 1.34 (0.50–2.18) | 0.87 |
| Men | 0.16 (−0.26 to 0.58) | 0.19 |
A large treatment association for women, and none for men [JAMA Oto 2018].
That is the opposite of how this subject is usually framed. The authors describe it as a large improvement in women with no improvement in men, and call for further study.
Hold it as a subgroup finding. It comes from a cohort rather than a randomised trial, the split was not the primary question, and with 67 women it is a modest sample. Subgroup analyses generate hypotheses. But it is consistent with the men's trial above also failing to show a between-arm erectile function benefit — two different studies, both finding less for men than expected.
Tier 2 for the association and for the women's finding. How we grade evidence.
What to take from this
If you have apnea and sexual dysfunction, the two may be related, and treating the apnea is not a reliable treatment for the dysfunction. Both statements are supported. Going into CPAP expecting it to resolve erectile dysfunction is setting up disappointment the evidence predicts.
Get the dysfunction assessed on its own terms. Erectile dysfunction is an independent cardiovascular risk marker and has its own workup — vascular, hormonal, medication-related, psychological. The apnea trial authors specifically recommend screening for it in apnea patients, which means treating it as a finding to investigate rather than a symptom to wait out.
If you are a woman with apnea, this is worth knowing exists. The subject is framed almost entirely around men, the screening tools already under-detect apnea in women, and the one study looking at sexual quality of life found the benefit concentrated in women. Why sleep apnea gets missed in women.
Treat the apnea for the reasons that are firm. Sleepiness, daytime function, quality of life. Those are what CPAP is best supported for, and they are sufficient reason. What happens after a diagnosis.
And do not reach for testosterone as the fix. A randomised trial found testosterone therapy worsened oxygen desaturation and sleep at seven weeks in obese men with severe apnea. If both are on the table, the sequencing matters and it is a clinician's call. Snoring and testosterone.
The line
No consumer product treats obstructive sleep apnea or sexual dysfunction. If both are present, neither is addressed by anything sold for snoring. Snoring versus sleep apnea.